Cardiovascular-Kidney-Metabolic (CKM) Syndrome: New Developments in Symptoms, Diagnosis, and Treatment
Abstract views: 0
/ 
PDF downloads: 0
DOI:
https://doi.org/10.5281/zenodo.17838183Keywords:
Cardiovascular Disease, Chronic Kidney Disease, Cardiovascular Kidney Metabolic Syndrome, Diabetes Mellitus, ObesityAbstract
The association between obesity, type 2 Diabetes Mellitus (DM), cardiovascular disease (CVD), and chronic kidney disease (CKD) is increasingly and widely recognized in developed countries. This condition has been collectively defined by the American Heart Association (AHA) as the Cardiovascular-Kidney-Metabolic (CKM) syndrome, which is characterized by hyperglycemia, insulin resistance, and increased activity of the renin-angiotensin-aldosterone system (RAAS), formation of advanced glycation end products, oxidative stress, lipotoxicity, endoplasmic reticulum stress, abnormal calcium handling, mitochondrial dysfunction and impaired energy production, and chronic inflammation. Addressing their prevention, management, and treatment is of paramount importance to improve patient health outcomes. The aim of this review is to provide a comprehensive overview of the status and new treatment modalities for the recently described CKM syndrome.
References
Agarwal, S., Shlipak, M. G., Kramer, H., Jain, A., & Herrington, D. M. (2012). The association of chronic kidney disease and metabolic syndrome with incident cardiovascular events: multiethnic study of atherosclerosis. Cardiology Research and Practice, 2012(1), 806102.
Al Ojaimi, M., Banimortada, B. J., Othman, A., Riedhammer, K. M., Almannai, M., & El‐Hattab, A. W. (2022). Disorders of histone methylation: molecular basis and clinical syndromes. Clinical Genetics, 102(3), 169-181.
Batko, K., Sączek, A., Banaszkiewicz, M., Małyszko, J., Koc-Żórawska, E., Żórawski, M., ... & Krzanowska, K. (2024). Comprehensive assessment of Cardiovascular-Kidney-Metabolic (CKM) syndrome: Novel tools for assessment of cardiovascular risk and kidney outcomes in long-term kidney transplant patients. Polish Heart Journal (Kardiologia Polska).
Bedo, D., Beaudrey, T., & Florens, N. (2024). Unraveling Chronic Cardiovascular and Kidney Disorder through the Butterfly Effect. Diagnostics, 14(5), 463.
Calabresi, P., Mechelli, A., Natale, G., Volpicelli-Daley, L., Di Lazzaro, G., & Ghiglieri, V. (2023). Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death & Disease, 14(3), 176.
Campos, G. M., Mazzini, G. S., Altieri, M. S., Docimo Jr, S., DeMaria, E. J., Rogers, A. M., ... & for Metabolic, S. (2021). ASMBS position statement on the rationale for performance of upper gastrointestinal endoscopy before and after metabolic and bariatric surgery. Surgery for Obesity and Related Diseases, 17(5), 837-847.
Cases, A., Broseta, J. J., Marqués, M., Cigarrán, S., Julián, J. C., Alcázar, R., & Ortiz, A. (2024). Cardiovascular-kidney-metabolic syndrome definition and its role in the prevention, risk staging, and treatment. An opportunity for the Nephrology. Nefrología (English Edition).
Cenko, E., Badimon, L., Bugiardini, R., Claeys, M. J., De Luca, G., de Wit, C., ... & Tousoulis, D. (2021). Cardiovascular disease and COVID-19: a consensus paper from the ESC working group on coronary pathophysiology & microcirculation, ESC working group on thrombosis and the association for acute CardioVascular care (ACVC), in collaboration with the European heart rhythm association (EHRA). Cardiovascular Research, 117(14), 2705-2729.
Chen, A., He, Q., Wu, Y., Chen, J., Ma, X., Wang, G., ... & Jia, Y. (2024). Incidence of cardiovascular-kidney-metabolic syndrome and its risk factors for progression in China. medRxiv, 2024-08.
Choi, Y., Jacobs Jr, D. R., Shroff, G. R., Kramer, H., Chang, A. R., & Duprez, D. A. (2022). Progression of chronic kidney disease risk categories and risk of cardiovascular disease and total mortality: coronary artery risk development in young adults cohort. Journal of the American Heart Association, 11(21), e026685.
Ciccarelli, M., Dawson, D., Falcao-Pires, I., Giacca, M., Hamdani, N., Heymans, S., ... & Thum, T. (2021). Reciprocal organ interactions during heart failure: a position paper from the ESC Working Group on Myocardial Function. Cardiovascular Research, 117(12), 2416-2433.
Claudel, S. E., Schmidt, I. M., Waikar, S. S., & Verma, A. (2024). Prevalence and Cumulative Incidence of Mortality Associated with Cardiovascular-Kidney-Metabolic Syndrome in the United States. medRxiv, 2024-03.
Davare, D. R., Mali, S. S., Patil, P. R., & Patil, R. R. (2024). Personalized Medicine Approaches in Drug Delivery: Tailoring Treatment to Individual Needs.
Dixon, S. L., & Isaac, M. (2023). No one-size-fits-all: critical narrative intervention and archeology of self as anti-racist and anti-colonial practices in body-focused repetitive behaviors. Health Education & Behavior, 50(4), 508-516.
Figuer, A., Alique, M., Valera, G., Serroukh, N., Ceprían, N., de Sequera, P., ... & Bodega, G. (2023). New mechanisms involved in the development of cardiovascular disease in chronic kidney disease. Nefrología (English Edition), 43(1), 63-80.
Garba, D. L., Razavi, A. C., Blumenthal, R. S., Stone, N. J., Polonsky, T., Khan, S. S., & Barouch, L. A. (2024). Advances in predicting cardiovascular risk: Applying the PREVENT equations. American Journal of Preventive Cardiology, 19, 100705.
Hannan, M., Ansari, S., Meza, N., Anderson, A. H., Srivastava, A., Waikar, S., ... & Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. (2021). Risk factors for CKD progression: overview of findings from the CRIC study. Clinical Journal of the American Society of Nephrology, 16(4), 648-659.
Hu, T., Liu, C. H., Lei, M., Zeng, Q., Li, L., Tang, H., & Zhang, N. (2024). Metabolic regulation of the immune system in health and diseases: mechanisms and interventions. Signal Transduction and Targeted Therapy, 9(1), 268.
Kanbay, M., Guldan, M., Ozbek, L., Copur, S., Covic, A. S., & Covic, A. (2024). Exploring the nexus: The place of kidney diseases within the cardiovascular-kidney-metabolic syndrome spectrum. European Journal of Internal Medicine.
Karmazyn, M., & Gan, X. T. (2023). Probiotics as potential treatments to reduce myocardial remodelling and heart failure via the gut-heart axis: state-of-the-art review. Molecular and Cellular Biochemistry, 478(11), 2539-2551.
Khan, S. S., Coresh, J., Pencina, M. J., Ndumele, C. E., Rangaswami, J., Chow, S. L., ... & American Heart Association. (2023). Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation, 148(24), 1982-2004.
Lange, A., Palka, V., Bian, C., Huntress, H., Morgan, J., Allwood, S., ... & Palka, P. (2023). Left heart remodelling in hypertensive patients: a comprehensive echocardiography and computed tomography study. Frontiers in Cardiovascular Medicine, 10, 1295537.
Lei, L., Li, J., Wang, W., Yu, Y., Pu, B., Peng, Y., ... & Guo, Y. (2024). Associations of Cardiovascular-Kidney-Metabolic syndrome with premature mortality and life expectancies in US adults: a cohort study. medRxiv, 2024-12.
Li, N., Li, Y., Cui, L., Shu, R., Song, H., Wang, J., ... & Wu, S. (2024). Association between different stages of cardiovascular-kidney-metabolic syndrome and the risk of all-cause mortality. Atherosclerosis, 397, 118585.
Li, M., Li, Q., Wei, J., Li, Y., Liu, F., Li, S., ... & Cao, J. (2024). Qualitative Study on the Real Experiences of Patients with Meige Syndrome Based on the Individual and Family Self-Management Theory. Patient Preference and Adherence, 2681-2696.
Logeshwaran, J., Adhikari, N., Joshi, S. S., Saxena, P., & Sharma, A. (2022). The deep DNA machine learning model to classify the tumor genome of patients with tumor sequencing. International Journal of Health Sciences, 6(S5), 9364-9375.
Masenga, S. K., Kabwe, L. S., Chakulya, M., & Kirabo, A. (2023). Mechanisms of oxidative stress in metabolic syndrome. International Journal of Molecular Sciences, 24(9), 7898.
Matsushita, K., Ballew, S. H., Wang, A. Y. M., Kalyesubula, R., Schaeffner, E., & Agarwal, R. (2022). Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nature Reviews Nephrology, 18(11), 696-707.
Miller, J. B., Hrabec, D., Krishnamoorthy, V., Kinni, H., & Brook, R. D. (2024). Evaluation and management of hypertensive emergency. BMJ, 386.
Minhas, A. M. K., Mathew, R. O., Sperling, L. S., Nambi, V., Virani, S. S., Navaneethan, S. D., ... & Abramov, D. (2024). Prevalence of the Cardiovascular-Kidney-Metabolic Syndrome in the United States. Journal of the American College of Cardiology, 83(18), 1824-1826.
Murton, M., Goff-Leggett, D., Bobrowska, A., Garcia Sanchez, J. J., James, G., Wittbrodt, E., ... & Tuttle, K. (2021). Burden of chronic kidney disease by KDIGO categories of glomerular filtration rate and albuminuria: a systematic review. Advances in Therapy, 38, 180-200.
Ndumele, C. E., Neeland, I. J., Tuttle, K. R., Chow, S. L., Mathew, R. O., Khan, S. S., ... & American Heart Association. (2023). A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation, 148(20), 1636-1664.
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., ... & American Heart Association. (2023). Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation, 148(20), 1606-1635.
Peng, J., Zhang, Y., Zhu, Y., Chen, W., Chen, L., Ma, F., ... & Huang, Z. (2024). Estimated glucose disposal rate for predicting cardiovascular events and mortality in patients with non-diabetic chronic kidney disease: a prospective cohort study. BMC Medicine, 22(1), 411.
Piko, N., Bevc, S., Ekart, R., Petreski, T., Hojs, N. V., & Hojs, R. (2021). Diabetic patients with chronic kidney disease: non-invasive assessment of cardiovascular risk. World Journal of Diabetes, 12(7), 975.
Rotariu, D., Babes, E. E., Tit, D. M., Moisi, M., Bustea, C., Stoicescu, M., ... & Bungau, S. G. (2022). Oxidative stress–Complex pathological issues concerning the hallmark of cardiovascular and metabolic disorders. Biomedicine & Pharmacotherapy, 152, 113238.
Sarma, S., Sockalingam, S., & Dash, S. (2021). Obesity as a multisystem disease: Trends in obesity rates and obesity‐related complications. Diabetes, Obesity and Metabolism, 23, 3-16.
Sebastian, S. A., Padda, I., & Johal, G. (2024). Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review. Current Problems in Cardiology, 49(2), 102344.
Silveira Rossi, J. L., Barbalho, S. M., Reverete de Araujo, R., Bechara, M. D., Sloan, K. P., & Sloan, L. A. (2022). Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors. Diabetes/Metabolism Research and Reviews, 38(3), e3502.
Shaftoe, J. B., & Gillis, T. E. (2024). Effects of hemodynamic load on cardiac remodeling in fish and mammals: the value of comparative models. Journal of Experimental Biology, 227(20).
Sheen, Y. J., & Sheu, W. H. H. (2011). Metabolic syndrome and renal injury. Cardiology Research and Practice, 2011(1), 567389.
Tanacli, R., Doeblin, P., Faragli, A., Hassel, J. H., Stehning, C., Plöckinger, U., ... & Kelle, S. (2025). Large Variations in Phenylalanine Concentrations Associate Adverse Cardiac Remodelling in Adult Patients With Phenylketonuria—A Long-Term CMR Study. Journal of Cachexia, Sarcopenia and Muscle, 16(1), e13667.
Tecce, N., De Alteriis, G., de Alteriis, G., Verde, L., Tecce, M. F., Colao, A., & Muscogiuri, G. (2024, March). Harnessing the Synergy of SGLT2 Inhibitors and Continuous Ketone Monitoring (CKM) in Managing Heart Failure among Patients with Type 1 Diabetes. In Healthcare (Vol. 12, No. 7, p. 753).
Tetteh, I., Spaulding, A., & Ptukhina, M. (2021). Understanding the job-hopping syndrome among millennial employees in the US food and agribusiness sector: a national survey. International Food and Agribusiness Management Review, 24(1), 89-104.
Tilg, H., Ianiro, G., Gasbarrini, A., & Adolph, T. E. (2024). Adipokines: masterminds of metabolic inflammation. Nature Reviews Immunology, 1-16.
Vanholder, R., Van Laecke, S., Glorieux, G., Verbeke, F., Castillo-Rodriguez, E., & Ortiz, A. (2018). Deleting death and dialysis: conservative care of cardio-vascular risk and kidney function loss in chronic kidney disease (CKD). Toxins, 10(6), 237.
Wu, X., Deng, H., Jian, S., Chen, H., Li, Q., Gong, R., & Wu, J. (2023). Global trends and hotspots in the digital therapeutics of autism spectrum disorders: a bibliometric analysis from 2002 to 2022. Frontiers in Psychiatry, 14, 1126404.
Xiao, H., Shao, X., Gao, P., Zou, H., & Zhang, X. (2022). Metabolic syndrome components and chronic kidney disease in a community population aged 40 years and older in southern China: a cross-sectional study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 839-848.
Zhang, H., Hu, Z., Wu, J., Li, Y., Jiang, S., Jin, L., ... & Hao, M. (2025). Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages Among Middle-Aged and Older Adults in China. JACC: Asia.
Zhang, S., Tang, S., Liu, Y., Xue, B., Xie, Q, Zhao, L., & Yuan, H. (2025). Protein-bound uremic toxins as therapeutic targets for cardiovascular, kidney, and metabolic disorders. Frontiers in Endocrinology, 16, 1500336.
Zoccali, C., Mallamaci, F., Halimi, M., Rossignol, P., Serafidis, P., De Caterina, R., ... & Zannad, F. (2023). From Cardio Renal Syndrome to Chronic Cardiovascular and Kidney Disorder: A Conceptual Transition. Clinical Journal of the American Society of Nephrology, 10-2215.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 GEVHER NESIBE JOURNAL OF MEDICAL AND HEALTH SCIENCES
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The journal is licensed under a 